[Antibody-targeted radio-chemotherapy of human primary liver cancer with radio-iodinated AFP monoclonal antibodies conjugated with mitomycin C: a preliminary clinical observation].
A "dual-warhead missile" made of 131I-AFP monoclonal antibody conjugated with mitomycin C was prepared. Twelve patients with moderately advanced and advanced primary liver cancer (PLC) were treated by i.v. injection of the antibody preparation. Tumor decrease in size was observed in 45.5% of the treated patients and decline in serum AFP level was seen in 83.3%. The one-year survival rate was 45.5%. Antibody-targeted radio-chemotherapy is a treatment of choice for advanced PLC patients.
Li
Z
Z
Cancer Hospital, Guangxi Medical University Nanning.
Wu
Y
Y
Zhou
D
D
D000328:Adult; D000903:Antibiotics, Antineoplastic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000628:therapy*; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000627:therapeutic use*; D015996:Survival Rate; D000509:alpha-Fetoproteins / Q000276:immunology
D000903:Antibiotics, Antineoplastic; D000911:Antibodies, Monoclonal; D000922:Immunotoxins; D007457:Iodine Radioisotopes; D000509:alpha-Fetoproteins; D016685:Mitomycin